Publications by authors named "Gary Frenette"
Article Synopsis
- - The study investigated the effects of the AKT inhibitor MK-2206 on patients with recurrent/metastatic adenoid cystic carcinoma (ACC), a rare and incurable cancer, aiming to reduce MYB expression and induce tumor regression.
- - Sixteen patients were treated but there were no confirmed responses; however, 13 maintained stable disease, with a median progression-free survival of 9.7 months and overall survival of 18 months.
- - While MK-2206 did decrease MYB levels in some patients, its clinical efficacy was limited, suggesting a need for new strategies to target MYB in ACC.
Molecular methodology to assess the impact of cancer chemotherapy on the oral bacterial flora: a pilot study.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod
April 2010
Objective: This pilot study determined the profile of the oral bacterial flora in an outpatient cancer population before and after chemotherapy using molecular techniques.
Study Design: We recruited 9 newly diagnosed breast cancer patients scheduled for induction chemotherapy. All were seen immediately before chemotherapy, and 7 to 14 days later.
Background: Metastatic melanoma is an incurable disease with an average survival of less than one year. Talabostat is a novel dipeptidyl peptidase inhibitor with immunostimulatory properties.
Methods: This phase II, open label, single arm study was conducted to evaluate the safety and efficacy of 75-100 mg/m2 cisplatin combined with 300-400 mcg talabostat bid for 6, 21-day cycles.
Purpose: This phase II study evaluated the efficacy and safety of sorafenib plus dacarbazine in patients with advanced melanoma.
Patients And Methods: This randomized, double-blind, placebo-controlled, multicenter study enrolled chemotherapy-naive patients with stage III (unresectable) or IV melanoma. A total of 101 patients received placebo plus dacarbazine (n = 50) or sorafenib plus dacarbazine (n = 51).
Background: Milataxel is a novel taxane analog, with evidence of enhanced preclinical activity compared to paclitaxel and docetaxel, especially in cell lines that over express P-glycoprotein. Based on preclinical data that milataxel may be active in colorectal cancer (CRC), a phase II study was performed in patients with advanced previously treated CRC.
Patients And Results: Forty-four eligible patients were entered.
Purpose: To assess the antitumor activity and toxicity of docetaxel plus cisplatin chemotherapy in patients with recurrent or incurable squamous cell carcinoma of the head and neck (SCCHN).
Patients And Methods: Patients with recurrent or incurable SCCHN were eligible if they were chemotherapy naive or if they had received one prior regimen as neoadjuvant or concurrent treatment with radiation. Patients who had received chemotherapy for recurrence or prior taxanes were ineligible.